Quality ID #118 (NQF 0066): Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)

- National Quality Strategy Domain: Effective Clinical Care
- Meaningful Measure Area: Management of Chronic Conditions

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES

MEASURES TYPE:

Process

DESCRIPTION:

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes OR a current or prior Left Ventricular Ejection Fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy

INSTRUCTIONS:

This measure is to be submitted a minimum of <u>once per performance period</u> for all patients with CAD seen during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure for the primary management of patients with CAD based on the services provided and the measure-specific denominator coding. Only patients who had at least two denominator eligible visits during the performance period will be counted for Submission Criteria 1 and 2 of this measure.

Measure Submission Type:

Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE:

1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40%

OR

2) Patients who are 18 years and older with a diagnosis of CAD who have diabetes

The MIPS eligible clinician should submit data on one of the submission criteria, depending on the clinical findings. If the patient has CAD and LVSD (without a diagnosis of Diabetes), use Denominator Submission Criteria 1. If the patient has CAD and Diabetes, use Denominator Submission Criteria 2. If the patient has both diabetes and LVSD, the eligible professional may submit quality data for Submission Criteria 2 and this will count as appropriate submission for this patient.

SUBMISSION CRITERIA 1: ALL PATIENTS WITH A DIAGNOSIS OF CAD WITH LVEF < 40% (WITHOUT A DIAGNOSIS OF DIABETES)

DENOMINATOR (SUBMISSION CRITERIA 1):

All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have a current or prior LVEF < 40%

Definition:

LVEF < 40% corresponds to qualitative documentation of moderate dysfunction or severe dysfunction.

DENOMINATOR NOTE: *Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.

Denominator Criteria (Eligible Cases):

Patients aged ≥ 18 years on date of encounter

AND

Diagnosis for coronary artery disease (ICD-10-CM): I20.0, I20.1, I20.8, I20.9, I21.01, I21.02, I21.09, I21.11, I21.19, I21.21, I21.29, I21.3, I21.4, I21.9, I21.A1, I21.A9, I22.0, I22.1, I22.2, I22.8, I22.9, I24.0, I24.1, I24.8, I24.9, I25.10, I25.110, I25.111, I25.118, I25.119, I25.2, I25.5, I25.6, I25.700, I25.701, I25.708, I25.709, I25.710, I25.711, I25.718, I25.719, I25.720, I25.721, I25.728, I25.729, I25.730, I25.731, I25.738, I25.739, I25.750, I25.751, I25.758, I25.759, I25.760, I25.761, I25.768, I25.769, I25.790, I25.791, I25.798, I25.799, I25.811, I25.812, I25.82, I25.83, I25.89, I25.9, I25.9, I25.5, I29.61

AND

Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241*, 99242*, 99243*, 99244*, 99245*, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350

WITHOUT

Telehealth Modifier: GQ, GT, 95, POS 02

ΔΝΓ

Two Denominator Eligible Visits

AND

Left Ventricular Ejection Fraction (LVEF) < 40% or documentation of moderately or severely depressed left ventricular systolic function: G8934

NUMERATOR (SUBMISSION CRITERIA 1):

Patients who were prescribed ACE inhibitor or ARB therapy

Definition:

Prescribed – May include prescription given to the patient for ACE inhibitor or ARB therapy at one or more visits in the measurement period OR patient already taking ACE inhibitor or ARB therapy as documented in current medication list.

NUMERATOR NOTE: Eligible clinicians who have given a prescription to the patient for or whose patient is currently taking a combination medication therapy, which contains either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (e.g., angiotensin receptor neprilysin inhibitor [ARNI, sacubitril/valsartan], ACEI+diuretic, ARB+diuretic, ACEI+calcium channel blocker) would meet performance for this measure.

Numerator Options:

Performance Met:

Clinician prescribed angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy (G8935)

Denominator Exception:

Clinician documented that patient was not an eligible candidate for angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy (eg, allergy, intolerance, pregnancy, renal failure due to ACE inhibitor, diseases of the aortic or mitral valve, other medical reasons) or (eg, patient declined, other patient reasons) or (eg, lack of drug availability, other reasons attributable to the health care system) (G8936)

<u>OR</u>

Performance Not Met:

Clinician did not prescribe angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy, reason not given (G8937)

<u>OR</u>

SUBMISSION CRITERIA 2: ALL PATIENTS WITH A DIAGNOSIS OF CAD WHO HAVE DIABETES

DENOMINATOR (SUBMISSION CRITERIA 2):

All patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes

Definition:

If a patient has both diabetes and LVSD, submission criteria #2 will count as appropriate submission for this patient.

DENOMINATOR NOTE: *Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.

Denominator Criteria (Eligible Cases):

Patients aged ≥ 18 years on date of encounter

AND

Diagnosis for coronary artery disease (ICD-10-CM): 120.0, 120.1, 120.8, 120.9, 121.01, 121.02, 121.09, 121.11, 121.19, 121.21, 121.29, 121.3, 121.4, 122.0, 122.1, 122.2, 122.8, 122.9, 124.0, 124.1, 124.8, 124.9, 125.10, 125.110, 125.111, 125.118, 125.119, 125.2, 125.5, 125.6, 125.700, 125.701, 125.708, 125.709, 125.710, 125.711, 125.718, 125.719, 125.720, 125.721, 125.728, 125.729, 125.730, 125.731, 125.738, 125.739, 125.739, 125.750, 125.751, 125.758, 125.759, 125.760, 125.761, 125.768, 125.769, 125.790, 125.791, 125.798, 125.799, 125.810, 125.811, 125.812, 125.82, 125.83, 125.89, 125.9, 295.1, 295.5, 298.61

AND

Diagnosis for diabetes (ICD-10-CM): E10.10, E10.11, E10.21, E10.22, E10.29, E10.311, E10.319, E10.3211, E10.3212, E10.3213, E10.3219, E10.3291, E10.3292, E10.3293, E10.3299, E10.3311, E10.3312, E10.3313, E10.3319, E10.3391, E10.3392, E10.3393, E10.3399, E10.3411, E10.3412, E10.3413, E10.3419, E10.3491, E10.3492, E10.3493, E10.3499, E10.3511, E10.3512, E10.3513, E10.3519, E10.3521, E10.3522, E10.3523, E10.3529, E10.3531, E10.3532, E10.3533, E10.3539, E10.3541, E10.3542, E10.3543, E10.3549, E10.3551, E10.3552, E10.3553, E10.3559, E10.3591, E10.3592, E10.3593, E10.3599, E10.36, E10.37X1, E10.37X2, E10.37X3, E10.37X9, E10.39, E10.40, E10.41, E10.42, E10.43, E10.44, E10.49, E10.51, E10.52, E10.59, E10.610, E10.618, E10.620, E10.621, E10.622, E10.628, E10.630, E10.638, E10.641, E10.649, E10.65, E10.69, E10.8, E10.9, E11.00, E11.01, E11.10, E11.11, E11.21, E11.22, E11.329, E11.311, E11.319, E11.37X1, E11.37X2, E11.37X3, E11.3312, E11.3313, E11.3319, E11.3391, E11.3392, E11.3393, E11.3399, E11.3411, E11.3412, E11.3413,

E11.3419. E11.3491. E11.3492. E11.3493. E11.3499. E11.3511. E11.3512. E11.3513. E11.3519. E11.3521, E11.3522, E11.3523, E11.3529, E11.3531, E11.3532, E11.3533, E11.3539, E11.3541, E11.3542, E11.3543, E11.3549, E11.3551, E11.3552, E11.3553, E11.3559, E11.3591, E11.3592, E11.3593, E11.3599, E11.36, E11.39, E11.40, E11.41, E11.42, E11.43, E11.44, E11.49, E11.51, E11.52, E11.59, E11.610, E11.618, E11.620, E11.621, E11.622, E11.628, E11.630, E11.638, E11.641, E11.649, E11.65, E11.69, E11.8, E11.9, E13.00, E13.01, E13.10, E13.11, E13.21, E13.22, E13.29, E13.311, E13.319, E13.3211, E13.3212, E13.3213, E13.3219, E13.3291, E13.3292, E13.3293, E13.3299, E13.3311, E13.3312, E13.3313, E13.3319, E13.3391, E13.3392, E13.3393, E13.3399, E13.3411, E13.3412, E13.3413, E13.3419, E13.3491, E13.3492, E13.3493, E13.3499, E13.3511, E13.3512, E13.3513, E13.3519, E13.3521, E13.3522, E13.3523, E13.3529, E13.3531, E13.3532, E13.3533, E13.3539, E13.3541, E13.3542, E13.3543, E13.3549, E13.3551, E13.3552, E13.3553, E13.3559, E13.3591, E13.3592, E13.3593, E13.3599, E13.36, E13.37X1, E13.37X2, E13.37X3, E13.37X9, E13.39, E13.40, E13.41, E13.42, E13.43, E13.44, E13.49, E13.51, E13.52, E13.59, E13.610, E13.618, E13.620, E13.621, E13.622, E13.628, E13.630, E13.638, E13.641, E13.649, E13.65, E13.69, E13.8, E13.9, O24.011, 024.012, 024.013, 024.019, 024.02, 024.03, 024.0111, 024.0112, 024.0113, 024.0119, 024.12, 024.13, 024.311, 024.312, 024.313, 024.319, 024.32, 024.33, 024.811, 024.812, 024.813, 024.819, O24.82, O24.83

<u>and</u>

Patient encounter during the performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241*, 99242*, 99243*, 99244*, 99245*, 99304, 99305, 99306, 99307, 99308, 99309, 99310, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350

WITHOUT

Telehealth Modifier: GQ, GT, 95, POS 02

AND

Two Denominator Eligible Visits

NUMERATOR (SUBMISSION CRITERIA 2):

Patients who were prescribed ACE inhibitor or ARB therapy

Definition:

Prescribed – May include prescription given to the patient for ACE inhibitor or ARB therapy at one ormore visits in the measurement period OR patient already taking ACE inhibitor or ARB therapy as documented in current medication list.

NUMERATOR NOTE: Eligible clinicians who have given a prescription to the patient for or whose patient is currently taking a combination medication therapy, which contains either an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) (e.g., angiotensin receptor neprilysin inhibitor [ARNI, sacubitril/valsartan], ACEI+diruretc, ARB+diruretic, ACEI+calcium channel blocker) would meet performance for this measure.

Numerator Options:

Performance Met:

Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy prescribed (G8473)

<u>OR</u>

Denominator Exception:

Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy not prescribed for reasons documented by the clinician (eg, allergy, intolerance, pregnancy, renal failure due to ACE inhibitor, diseases of the aortic or mitral valve, other medical reasons) or (eg, patient declined, other

patient reasons) or (eg, lack of drug availability, other reasons attributable to the health care system) (G8474)

<u>OR</u>

Performance Not Met:

Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy not prescribed, reason not given (G8475)

RATIONALE:

Nonadherence to cardioprotective medications is prevalent among outpatients with coronary artery disease and can be associated with a broad range of adverse outcomes, including all-cause and cardiovascular mortality, cardiovascular hospitalizations, and the need for revascularization procedures.

In the absence of contraindications, ACE inhibitors or ARBs are recommended for all patients with a diagnosis of coronary artery disease and diabetes or reduced left ventricular systolic function. ACE inhibitors remain the first choice, but ARBs can now be considered a reasonable alternative. Both pharmacologic agents have been shown to decrease the risk of death, myocardial infarction, and stroke. Additional benefits of ACE inhibitors include the reduction of diabetic symptoms and complications for patients with diabetes.

CLINICAL RECOMMENDATION STATEMENTS:

The following evidence statements are quoted verbatim from the referenced clinical guidelines.

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease (SIHD)

RENIN-ANGIOTENSIN-ALDOSTERONE BLOCKER THERAPY

ACE inhibitors should be prescribed in all patients with SIHD who also have hypertension, diabetes mellitus, LVEF 40% or less, or CKD, unless contraindicated. (Class I Recommendation Level of Evidence: A)

ARBs are recommended for patients with SIHD who have hypertension, diabetes mellitus, LV systolic dysfunction, or CKD and have indications for, but are intolerant of, ACE inhibitors. (Class I Recommendation, Level of Evidence: A)

COPYRIGHT:

Physician performance measures and related data specifications were developed by the American Medical Association (AMA) convened Physician Consortium for Performance Improvement® (PCPI®), the American College of Cardiology (ACC), and the American Heart Association (AHA) to facilitate quality improvement activities by physicians. These performance measures are not clinical guidelines and do not establish a standard of medical care, and have not been tested for all potential applications. While copyrighted, they can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the performance measures for commercial gain, or incorporation of the performance measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the measures require a license agreement between the user and the AMA (on behalf of the PCPI) or the ACC or the AHA. Neither the AMA, ACC, AHA, the PCPI nor its members shall be responsible for any use of these measures.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.


© 2018 American College of Cardiology, American Heart Association and American Medical Association. All Rights Reserved.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the ACC, the AHA, the PCPI

and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the measures specifications is copyright 2018 American Medical Association. LOINC® copyright 2004-2018 Regenstrief Institute, Inc. This material contains SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2018 International Health Terminology Standards Development Organization. All Rights Reserved. Use of SNOMED CT® is only authorized within the United States.


2019 Clinical Quality Measure Flow for Quality ID #118 NQF #0066: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy-Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%) Submission Criteria One



^{*}This measure has two submission criteria which should be aggregated to one calculation. Please refer to the sample calculation.

^{**}See the posted Measure Specification for specific coding and instructions to submit this measure.
***Left Ventricular Ejection Fraction < 40% has been moved to the denominator of this measure to identify the measure's intended eligible population more accurately. This flow should be followed very carefully since the eligible population in this flow differs from the one posted in the Measure Specification.

2019 Clinical Quality Measure Flow for Quality ID #118 NQF #0066: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy-Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) Submission Criteria Two



^{*}This measure has two submission criteria which should be aggregated to one calculation. Please refer to the sample calculation.

^{**}See the posted Measure Specification for specific coding and instructions to submit this measure.

^{**}If a patient is diagnosed with diabetes, Submission option #2 is appropriate for submitting on this patient.

2019 Clinical Quality Measure Flow Narrative for Quality ID #118 NQF #0066: Coronary Artery Disease (CAD): Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)

Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification.

Submission Criteria #1

- 1. Start with Denominator
- 2. Check Patient Age:
 - a. If Patient Age at Date of Service is greater than or equal to 18 Years equals No, do not include in Eligible Population. Stop Processing.
 - b. If Patient Age at Date of Service is greater than or equal to 18 Years equals Yes, proceed to check Patient Diagnosis.
- 3. Check Patient Diagnosis:
 - a. If Diagnosis for CAD as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
 - b. If Diagnosis for CAD as Listed in the Denominator equals Yes, proceed to check Left Ventricular Ejection Fraction < 40%.
- 4. Check Left Ventricular Ejection Fraction < 40%:
 - a. If Left Ventricular Ejection Fraction < 40% equals No, do not include in Eligible Population. Stop Processing.
 - b. If Left Ventricular Ejection Fraction < 40% equals Yes, proceed to check Encounter Performed.
- 5. Check Encounter Performed:
 - a. If Encounter as Listed in Denominator equals No, do not include in Eligible Population. Stop Processing.
 - b. If Encounter as Listed in Denominator equals Yes, proceed to check Telehealth Modifier.
- 6. Check Telehealth Modifier:
 - a. If Telehealth Modifier equals Yes, do not include in Eligible Population. Stop Processing.
 - b. If Telehealth Modifier equals No, proceed to check Encounter Performed.
- 7. Check Encounter Performed:
 - a. If Two Denominator Eligible Visits equals No, do not include in Eligible Population. Stop Processing.
 - b. If Two Denominator Eligible Visits equals Yes, proceed to check Diagnosis.
- 8. Check Diagnosis of Diabetes:

- a. If Diagnosis of Diabetes as Listed in the Denominator equals Yes, proceed to Submission Criteria #2.
- b. If Diagnosis of Diabetes as Listed in the Denominator equals No, include in Eligible Population.
- 9. Denominator Population:
 - a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation.
- 10. Check Clinician Prescribed Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy:
 - a. If Clinician Prescribed Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy equals Yes, include in Data Completeness Met and Performance Met.
 - b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a¹ equals 40 patients in Sample Calculation.
 - c. If Clinician Prescribed Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy equals No, proceed to Clinician Documented That Patient Was Not an Eligible Candidate for Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy.
- 11. Check Clinician Documented That Patient Was Not an Eligible Candidate for Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy:
 - a. If Clinician Documented That Patient Was Not an Eligible Candidate for Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy equals Yes, include in Data Completeness Met and Denominator Exception.
 - b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter b¹ equals 10 patients in the Sample Calculation.
 - c. If Clinician Documented That Patient Was Not an Eligible Candidate for Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy equals No, proceed to check Clinician Did Not Prescribe Angiotensin Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy, Reason Not Given.
- 12. Check Clinician Did Not Prescribe Angiotensin Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy, Reason not Given:
 - a. If Clinician Did Not Prescribe Angiotensin Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy, Reason Not Given equals Yes, include in the Data Completeness Met and Performance Not Met.
 - b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c¹ equals 20 patients in the Sample Calculation.
 - c. If Clinician Did Not Prescribe Angiotensin Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy, Reason Not Given equals No, proceed to check Data Completeness Not Met.

- 13. Check Data Completeness Not Met:
 - a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

SAMPLE CALCULATIONS: Data Completeness= Performance Met (a¹+a²=80 patients) + Denominator Exception (b¹+b²=20 patients) + Performance Not Met (c¹+c²=40 patients) = 140 pts = 87.50% Eligible Population / Denominator (d¹+d²=160 patients) = 160 pts = 160 pts Performance Rate= Performance Met (a¹+a²=80 patients) = 80 pts. = 66.67% Data Completeness Numerator (140 patients) - Denominator Exception (b¹+b²=20 patients) = 120 pts.

2019 Clinical Quality Measure Flow Narrative for Quality ID

#118 NQF #0066: Coronary Artery Disease (CAD): Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)

Start Submission Criteria #2

- 1. Start with Denominator
- 2. Check Patient Age:
 - a. If Patient Age at Date of Service is greater than or equal to 18 Years equals No, do not include in Eligible Population. Stop Processing.
 - b. If Patient Age at Date of Service is greater than or equal to 18 Years equals Yes, proceed to check Patient Diagnosis.
- 3. Check Patient Diagnosis:
 - a. If Diagnosis for CAD as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
 - b. If Diagnosis for CAD as Listed in the Denominator equals Yes, proceed to check Encounter Performed.
- 4. Check Encounter Performed:
 - a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
 - b. If Encounter as Listed in the Denominator equals Yes, proceed to check Telehealth Modifier.
- 5. Check Telehealth Modifier:
 - a. If Telehealth Modifier equals Yes, do not include in Eligible Population. Stop Processing.
 - b. If Telehealth Modifier equals No, proceed to check Encounter Performed.
- 6. Check Encounter Performed:
 - a. If Two Denominator Eligible Visits equals No, do not include in Eligible Population. Stop Processing.
 - b. If Two Denominator Eligible Visits equals Yes, proceed to check Diagnosis of Diabetes.
- 7. Check Diagnosis of Diabetes:
 - a. If Diagnosis of Diabetes as Listed in the Denominator equals No, proceed to Submission Criteria #1.
 - b. If Diagnosis of Diabetes as Listed in the Denominator equals Yes, include in Eligible Population.
- 8. Denominator Population:
 - a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d² equals 80 patients in the Sample Calculation.

- 9. Check Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Prescribed:
 - a. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Prescribed equals Yes, include in Data Completeness Met and Performance Met.
 - b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a² equals 40 patients in Sample Calculation.
 - c. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Prescribed equals No, proceed to check Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Not Prescribed for Reasons Documented by the Clinician.
- 10. Check Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Not Prescribed for Reasons Documented by the Clinician:
 - a. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Not Prescribed for Reasons Documented by the Clinician equals Yes, include in Data Completeness Met and Denominator Exception.
 - b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b² equals 10 patients in the Sample Calculation.
 - c. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Not Prescribed for Reasons Documented by the Clinician equals No, proceed to check Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Not Prescribed, Reason Not Given.
- 11. Check Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Not Prescribed. Reason Not Given:
 - a. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Not Prescribed, Reason Not Given equals Yes, include in the Data Completeness Met and Performance Not Met.
 - b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c² equals 20 patients in the Sample Calculation.
 - c. If Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Not Prescribed, Reason Not Given equals No, proceed to check Data Completeness Not Met.
- 12. Check Data Completeness Not Met:
 - a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

SAMPLE CALCULATIONS:

Data Completeness=
Performance Met (a¹+a²=80 patients) + Denominator Exception (b¹+b²=20 patients) + Performance Not Met (c¹+c²=40 patients) = 140 pts = 87.50%
Eligible Population / Denominator (d¹+d²=160 patients) = 160 pts

Performance Rate= $\frac{\text{Performance Met (a}^{1} + \text{a}^{2} = 80 \text{ patients)}}{\text{Data Completeness Numerator (140 patients)} - \text{Denominator Exception (b}^{1} + \text{b}^{2} = 20 \text{ patients)}} = \frac{80 \text{ pts.}}{120 \text{ pts.}} = \frac{80 \text{ pts.}}{120 \text{ pts.}}$